fluorouracil has been researched along with Symptom Cluster in 96 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib." | 9.19 | Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014) |
| "Capecitabine is an established therapy for metastatic breast cancer." | 9.14 | Study of low-dose capecitabine monotherapy for metastatic breast cancer. ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010) |
| "To determine whether concurrent pyridoxine therapy can prevent the development of hand-foot syndrome (HFS) in patients being treated with capecitabine." | 9.14 | Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. ( Chang, HM; Chun, YJ; Kang, YK; Kim, MS; Kim, TW; Lee, JL; Lee, SS; Lee, SY; Ryu, MH; Yoon, DH, 2010) |
| "For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used." | 9.14 | A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. ( Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP, 2009) |
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 9.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| "This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer." | 9.11 | A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004) |
| "Hand-foot syndrome (HFS) has been previously reported as a side effect in 45-56% of patients treated with capecitabine." | 9.10 | Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. ( Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED, 2002) |
| "An unusual syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia is associated with a PALA-fluorouracil regimen." | 9.07 | A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991) |
| " The following key terms were used in the search: hand-foot syndrome, palmar-plantar erythrodysesthesia, capecitabine, Xeloda, colorectal cancer, and metastatic breast cancer." | 8.83 | Management of hand-foot syndrome induced by capecitabine. ( Gressett, SM; Hardwicke, F; Stanford, BL, 2006) |
| "Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine." | 8.82 | Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). ( Hoff, P; Lassere, Y, 2004) |
| "Hand-and-foot syndrome (HFS) is one of the well-known adverse events associated with capecitabine, a prodrug of 5-fluorouracil (5-FU)." | 8.82 | Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. ( Hitti, IF; Narasimhan, P; Narasimhan, S; Rachita, M, 2004) |
| "Hand-foot syndrome is a localized cutaneous side effect associated with the administration of several chemotherapeutic agents, including the oralfluoropyrimidine capecitabine (Xeloda)." | 8.82 | Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. ( Blum, J; Scheithauer, W, 2004) |
| "Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with potentially life-threatening toxicity following the administration of standard doses of 5-fluorouracil." | 8.82 | Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. ( Diasio, R; Ezzeldin, H, 2004) |
| "Cholinergic syndrome is an acute adverse reaction associated with irinotecan." | 7.88 | Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. ( Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T, 2018) |
| "Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer." | 7.77 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011) |
| "A hospital based cross-sectional retrospective study was conducted to determine the frequency of hand foot syndrome (HFS) with Capecitabine as a single agent and in combination with Oxaliplatin." | 7.76 | High frequency of hand foot syndrome with capecitabine. ( Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N, 2010) |
| "Hand-foot syndrome is a common adverse effect of therapy with capecitabine (Xeloda) for the treatment of various carcinomas." | 7.76 | Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding. ( Fraga, G; Gadzia, J; Latif, S, 2010) |
| " The objective of our study was to describe the incidence and response to treatment of the hand-foot syndrome (HFS) and the compliance with treatment of patients with stage IIB, IIIA, IIIB, and IIIC colon cancer that were treated with capecitabine alone as adjuvant therapy." | 7.75 | Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. ( Chun, HK; Lee, WS; Lee, WY; Son, HS; Yun, SH, 2009) |
| "Capecitabine is one of the most effective oral regimens of chemotherapy against advanced or recurrent breast cancer." | 7.74 | [Management of hand-foot syndrome in patient treated with capecitabine]. ( Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y, 2008) |
| "A 72-year-old patient with esophageal carcinoma developed a severe hand-foot syndrome during second-line therapy with the oral fluoropyrimidine capecitabine." | 7.74 | [Hand-foot syndrome with capecitabine therapy]. ( Hengge, UR; Marini, A, 2007) |
| "We present a case of hand-foot syndrome (HFS) induced by bolus 5-fluorouracil (5-FU) therapy." | 7.74 | [A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy]. ( Aoyagi, H; Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kobayashi, H; Matsuyama, T; Sugihara, K; Uetake, H; Yasuno, M, 2008) |
| "A 41-year-old woman who was undergoing oral chemotherapy with capecitabine for metastatic breast cancer presented with recurrent episodes of chest pain associated with electrocardiographic signs of diffuse ST segment elevation." | 7.73 | Acute coronary syndrome induced by oral capecitabine. ( Cardinale, D; Colombo, A; Colombo, N, 2006) |
| "Clinical characteristics and risk factors of hand-foot syndrome were investigated in patients who received capecitabine-containing chemotherapy." | 7.72 | Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. ( Ahn, JH; Chang, HM; Cho, HK; Heo, YS; Kang, YK; Kim, SB; Kim, TW; Kim, WK; Lee, JS; Ryu, MH, 2004) |
| " We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib." | 7.71 | Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002) |
| "The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy." | 7.69 | Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997) |
| "Nine patients (nine eyes) with iridocorneal endothelial (ICE) syndrome underwent trabeculectomy and received postoperative subconjunctival injections of 5-fluorouracil (5-FU) to enhance bleb formation (total 5-FU dose, 30-105 mg; mean, 53." | 7.68 | 5-Fluorouracil after trabeculectomy and the iridocorneal endothelial syndrome. ( Cristol, SM; Grajewski, AL; Parrish, RK; Wright, MM, 1991) |
| "A case of palmar-plantar erythrodysesthesia syndrome (PPES) observed during a 120-h infusion of 5-fluorouracil (5-FU) is presented." | 7.67 | Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. ( Bellmunt, J; Hidalgo, R; Navarro, M; Solé, LA, 1988) |
| "Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials." | 6.71 | Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003) |
| "Capecitabine is a chemotherapeutic drug for use in cancers." | 5.35 | Topical henna for capecitabine induced hand-foot syndrome. ( Guzin, G; Yucel, I, 2008) |
| "Capecitabine was developed as a prodrug of 5-fluorouracil (FU), with the goal of improving tolerability and intratumour drug concentrations through tumour-specific conversion to the active drug against numerous types of neoplasms." | 5.34 | Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? ( Do, JE; Kim, YC, 2007) |
| "This patient with DPD deficiency manifested a variant of HFS." | 5.33 | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006) |
| "Coronary artery spasm has been postulated to be involved in the mechanism of this incident Patients may present with angina, myocardial infarction, arrhythmias and/or even sudden death." | 5.31 | A case of coronary spasm induced by 5-fluorouracil. ( Celik, S; Gorgulu, S; Tezel, T, 2002) |
| "Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib." | 5.19 | Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014) |
| "For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used." | 5.14 | A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. ( Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP, 2009) |
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 5.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| "To compare the efficacy and toxicity of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin (5-Fu/LV) plus oxaliplatin (FOLFOX4) regimens as adjuvant chemotherapy for stage III colorectal cancer." | 5.14 | [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer]. ( Fang, F; Li, DC; Lu, GC, 2010) |
| "To determine whether concurrent pyridoxine therapy can prevent the development of hand-foot syndrome (HFS) in patients being treated with capecitabine." | 5.14 | Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. ( Chang, HM; Chun, YJ; Kang, YK; Kim, MS; Kim, TW; Lee, JL; Lee, SS; Lee, SY; Ryu, MH; Yoon, DH, 2010) |
| "Capecitabine is an established therapy for metastatic breast cancer." | 5.14 | Study of low-dose capecitabine monotherapy for metastatic breast cancer. ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010) |
| "Effects of a single administration of small doses of 5-fluorouracil on results of skin plasty for syndrome of the diabetic foot were studied in 61 patients who had undergone local operations for pyo-necrotic diseases of the foot against the background of diabetes mellitus." | 5.12 | [Effects of short-term immunosuppression on the engraftment of skin transplants at syndrome of the diabetic foot]. ( Belov, VV; Bordunovskiĭ, VN; Grekova, NM; Lebedeva, IuV; Tertyshnik, SS, 2007) |
| "This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer." | 5.11 | A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004) |
| "Hand-foot syndrome (HFS) has been previously reported as a side effect in 45-56% of patients treated with capecitabine." | 5.10 | Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. ( Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED, 2002) |
| "An unusual syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia is associated with a PALA-fluorouracil regimen." | 5.07 | A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991) |
| "Hand-foot syndrome is a highly unpleasant adverse reaction caused by treatment protocols containing capecitabine (an orally administered drug), docetaxel, liposomal doxorubicin infusions or continuously infused 5-fluorouracil." | 4.87 | [Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy]. ( Bartal, A; Liszkay, G; Mátrai, Z; Szûcs, A, 2011) |
| " The following key terms were used in the search: hand-foot syndrome, palmar-plantar erythrodysesthesia, capecitabine, Xeloda, colorectal cancer, and metastatic breast cancer." | 4.83 | Management of hand-foot syndrome induced by capecitabine. ( Gressett, SM; Hardwicke, F; Stanford, BL, 2006) |
| "Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with potentially life-threatening toxicity following the administration of standard doses of 5-fluorouracil." | 4.82 | Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. ( Diasio, R; Ezzeldin, H, 2004) |
| "Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine." | 4.82 | Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). ( Hoff, P; Lassere, Y, 2004) |
| "Hand-and-foot syndrome (HFS) is one of the well-known adverse events associated with capecitabine, a prodrug of 5-fluorouracil (5-FU)." | 4.82 | Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. ( Hitti, IF; Narasimhan, P; Narasimhan, S; Rachita, M, 2004) |
| "Hand-foot syndrome is a localized cutaneous side effect associated with the administration of several chemotherapeutic agents, including the oralfluoropyrimidine capecitabine (Xeloda)." | 4.82 | Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. ( Blum, J; Scheithauer, W, 2004) |
| " Also, as the veins in the lower extremity were filled with thrombus, we gave him an anticoagulant (Edoxaban), but due to the malignant hyper coagulable state (Trousseau syndrome) a CV port could not be implanted." | 3.91 | [A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome]. ( Hirai, A; Ichiki, Y; Imanishi, N; Ishida, T; Kusanagi, K; Shinohara, S; Takeda, Y; Tanaka, F; Tashima, Y; Yoshimatsu, K, 2019) |
| "Cholinergic syndrome is an acute adverse reaction associated with irinotecan." | 3.88 | Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. ( Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T, 2018) |
| "The association of motilin, ghrelin, leptin, gastrin, pepsinogen (PG) I and II with cancer chemotherapy-associated dyspepsia syndrome (CADS) was investigated in 35 patients with breast cancer receiving first cycle of 5-fluorouracil, cyclophosphamide, epirubicin (FEC60) chemotherapy." | 3.79 | Gut peptide profile and chemotherapy-associated dyspepsia syndrome in patients with breast cancer undergoing FEC60 chemotherapy. ( Campanella, G; Clemente, C; D'Attoma, B; Giotta, F; Linsalata, M; Orlando, A; Riezzo, G; Russo, F, 2013) |
| "Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer." | 3.77 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011) |
| "A hospital based cross-sectional retrospective study was conducted to determine the frequency of hand foot syndrome (HFS) with Capecitabine as a single agent and in combination with Oxaliplatin." | 3.76 | High frequency of hand foot syndrome with capecitabine. ( Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N, 2010) |
| "Hand-foot syndrome is a common adverse effect of therapy with capecitabine (Xeloda) for the treatment of various carcinomas." | 3.76 | Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding. ( Fraga, G; Gadzia, J; Latif, S, 2010) |
| " The objective of our study was to describe the incidence and response to treatment of the hand-foot syndrome (HFS) and the compliance with treatment of patients with stage IIB, IIIA, IIIB, and IIIC colon cancer that were treated with capecitabine alone as adjuvant therapy." | 3.75 | Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. ( Chun, HK; Lee, WS; Lee, WY; Son, HS; Yun, SH, 2009) |
| "We present a case of hand-foot syndrome (HFS) induced by bolus 5-fluorouracil (5-FU) therapy." | 3.74 | [A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy]. ( Aoyagi, H; Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kobayashi, H; Matsuyama, T; Sugihara, K; Uetake, H; Yasuno, M, 2008) |
| "Capecitabine is one of the most effective oral regimens of chemotherapy against advanced or recurrent breast cancer." | 3.74 | [Management of hand-foot syndrome in patient treated with capecitabine]. ( Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y, 2008) |
| "A 72-year-old patient with esophageal carcinoma developed a severe hand-foot syndrome during second-line therapy with the oral fluoropyrimidine capecitabine." | 3.74 | [Hand-foot syndrome with capecitabine therapy]. ( Hengge, UR; Marini, A, 2007) |
| "A 41-year-old woman who was undergoing oral chemotherapy with capecitabine for metastatic breast cancer presented with recurrent episodes of chest pain associated with electrocardiographic signs of diffuse ST segment elevation." | 3.73 | Acute coronary syndrome induced by oral capecitabine. ( Cardinale, D; Colombo, A; Colombo, N, 2006) |
| "Clinical characteristics and risk factors of hand-foot syndrome were investigated in patients who received capecitabine-containing chemotherapy." | 3.72 | Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. ( Ahn, JH; Chang, HM; Cho, HK; Heo, YS; Kang, YK; Kim, SB; Kim, TW; Kim, WK; Lee, JS; Ryu, MH, 2004) |
| " We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib." | 3.71 | Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002) |
| "For almost 40 years, 5-fluorouracil (5-FU) has been the only useful drug with clinically meaningful activity in metastatic colorectal carcinoma." | 3.70 | Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer. ( Au, E; Khoo, KS; Koo, WH; Lim, WT, 1999) |
| "The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy." | 3.69 | Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997) |
| "Nine patients (nine eyes) with iridocorneal endothelial (ICE) syndrome underwent trabeculectomy and received postoperative subconjunctival injections of 5-fluorouracil (5-FU) to enhance bleb formation (total 5-FU dose, 30-105 mg; mean, 53." | 3.68 | 5-Fluorouracil after trabeculectomy and the iridocorneal endothelial syndrome. ( Cristol, SM; Grajewski, AL; Parrish, RK; Wright, MM, 1991) |
| "The watery diarrhea-hypokalemia-achlorhydria syndrome associated with ectopic secretion of vasoactive intestinal peptide has only been conclusively documented with tumors originating in the pancreas or sympathetic chain." | 3.67 | Watery diarrhea-hypokalemia-achlorhydria syndrome and carcinoma of the esophagus. ( Douglas, MC; Hurley, R; Kalnins, R; Moran, L; Shulkes, A; Smallwood, RA; Watson, KJ, 1985) |
| "A case of palmar-plantar erythrodysesthesia syndrome (PPES) observed during a 120-h infusion of 5-fluorouracil (5-FU) is presented." | 3.67 | Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. ( Bellmunt, J; Hidalgo, R; Navarro, M; Solé, LA, 1988) |
| "Following gastrectomy for locally advanced adenocarcinomas, three patients developed microangiopathic hemolytic anemia and renal failure shortly after completing courses of adjuvant chemotherapy with mitomycin and 5-FU." | 3.66 | Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome. ( Band, PR; Bettez, P; Giroux, L; Gruber, J; Jolivet, J; Laurin, S, 1983) |
| "Hyperpigmentation is a rare side effect occurring with 5-FU infusions; it has been reported in 2-5% of patients." | 2.82 | Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review. ( Basu, D; Chaudhary, K; Goel, V; Jain, A; Narayan, S; Redhu, P; Soni, S; Talwar, V, 2022) |
| "Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials." | 2.71 | Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003) |
| " HFS is a leading cause of treatment interruption, dosage reduction, or, even, therapy discontinuation for patients on a capecitabine regimen." | 2.44 | Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? ( Goldberg, RM; McLeod, HL; Yen-Revollo, JL, 2008) |
| "Palmar-plantar erythrodysesthesia (PPE) or hand-foot syndrome (HFS) is a relatively common side effect of cytotoxic chemotherapy." | 2.44 | Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. ( Harrold, K; How, C; Webster-Gandy, JD, 2007) |
| "Capecitabine is a chemotherapeutic drug for use in cancers." | 1.35 | Topical henna for capecitabine induced hand-foot syndrome. ( Guzin, G; Yucel, I, 2008) |
| "Capecitabine was developed as a prodrug of 5-fluorouracil (FU), with the goal of improving tolerability and intratumour drug concentrations through tumour-specific conversion to the active drug against numerous types of neoplasms." | 1.34 | Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? ( Do, JE; Kim, YC, 2007) |
| "This patient with DPD deficiency manifested a variant of HFS." | 1.33 | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006) |
| "Coronary artery spasm has been postulated to be involved in the mechanism of this incident Patients may present with angina, myocardial infarction, arrhythmias and/or even sudden death." | 1.31 | A case of coronary spasm induced by 5-fluorouracil. ( Celik, S; Gorgulu, S; Tezel, T, 2002) |
| "Leser-Trélat-syndrome is characterized as the eruptive appearance of multiple seborrheic keratoses in association with underlying malignant disease." | 1.31 | [Clinical and histopathological characteristics of early Leser-Trélat syndrome]. ( Barth, G; Basten, O; Rompel, R; Rüschoff, J, 2001) |
| "The expanding use of cytotoxic drugs in cancer therapy has resulted in a confusing and increasingly frequent array of severe renal complications." | 1.27 | Renal complications of cytotoxic therapy. ( Clarkson, AR; Healy, HG, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (25.00) | 18.7374 |
| 1990's | 10 (10.42) | 18.2507 |
| 2000's | 45 (46.88) | 29.6817 |
| 2010's | 16 (16.67) | 24.3611 |
| 2020's | 1 (1.04) | 2.80 |
| Authors | Studies |
|---|---|
| Narayan, S | 3 |
| Talwar, V | 3 |
| Redhu, P | 3 |
| Goel, V | 3 |
| Jain, A | 3 |
| Soni, S | 3 |
| Chaudhary, K | 3 |
| Basu, D | 3 |
| Kanbayashi, Y | 1 |
| Ishikawa, T | 2 |
| Kanazawa, M | 1 |
| Nakajima, Y | 1 |
| Tabuchi, Y | 1 |
| Kawano, R | 1 |
| Yoshioka, T | 1 |
| Yoshida, N | 1 |
| Hosokawa, T | 1 |
| Takayama, K | 1 |
| Taguchi, T | 2 |
| Tashima, Y | 1 |
| Kusanagi, K | 1 |
| Takeda, Y | 1 |
| Yoshimatsu, K | 1 |
| Ishida, T | 1 |
| Shinohara, S | 1 |
| Hirai, A | 1 |
| Imanishi, N | 1 |
| Ichiki, Y | 1 |
| Tanaka, F | 1 |
| Riezzo, G | 1 |
| Clemente, C | 1 |
| Linsalata, M | 1 |
| D'Attoma, B | 1 |
| Orlando, A | 1 |
| Campanella, G | 1 |
| Giotta, F | 1 |
| Russo, F | 1 |
| Goto, N | 1 |
| Mimura, J | 1 |
| Saura, C | 1 |
| Garcia-Saenz, JA | 2 |
| Xu, B | 1 |
| Harb, W | 1 |
| Moroose, R | 1 |
| Pluard, T | 1 |
| Cortés, J | 1 |
| Kiger, C | 1 |
| Germa, C | 1 |
| Wang, K | 1 |
| Martin, M | 2 |
| Baselga, J | 1 |
| Kim, SB | 2 |
| Matsuda, S | 1 |
| Koketsu, H | 1 |
| Hayakawa, M | 1 |
| Nagata, N | 1 |
| Browall, M | 1 |
| Brandberg, Y | 1 |
| Nasic, S | 1 |
| Rydberg, P | 1 |
| Bergh, J | 1 |
| Rydén, A | 1 |
| Xie, H | 1 |
| Eriksson, I | 1 |
| Wengström, Y | 1 |
| Fujii, C | 1 |
| Anami, S | 1 |
| Fujino, M | 2 |
| Yasui, Y | 1 |
| Fujita, M | 1 |
| Inoue, M | 1 |
| Nakayama, T | 2 |
| Kamigaki, S | 1 |
| Tatsuta, M | 1 |
| Furukawa, H | 1 |
| Perboni, S | 1 |
| Bowers, C | 1 |
| Kojima, S | 1 |
| Asakawa, A | 1 |
| Inui, A | 1 |
| Hénin, E | 1 |
| You, B | 1 |
| VanCutsem, E | 1 |
| Hoff, PM | 2 |
| Cassidy, J | 1 |
| Twelves, C | 1 |
| Zuideveld, KP | 1 |
| Sirzen, F | 1 |
| Dartois, C | 1 |
| Freyer, G | 1 |
| Tod, M | 1 |
| Girard, P | 1 |
| Matsuyama, T | 1 |
| Uetake, H | 1 |
| Aoyagi, H | 1 |
| Kobayashi, H | 1 |
| Iida, S | 1 |
| Higuchi, T | 1 |
| Yasuno, M | 1 |
| Enomoto, M | 1 |
| Sugihara, K | 1 |
| Lee, YJ | 1 |
| Lee, HJ | 2 |
| Jeong, KC | 1 |
| Kang, JG | 1 |
| Lee, SH | 1 |
| Kim, YT | 1 |
| Son, HS | 1 |
| Lee, WY | 1 |
| Lee, WS | 1 |
| Yun, SH | 1 |
| Chun, HK | 1 |
| Latif, S | 1 |
| Fraga, G | 1 |
| Gadzia, J | 1 |
| Lu, GC | 1 |
| Fang, F | 1 |
| Li, DC | 1 |
| Masuda, N | 1 |
| Yoshidome, K | 1 |
| Akagi, K | 1 |
| Nishida, Y | 1 |
| Yoshikawa, Y | 1 |
| Ogino, N | 1 |
| Abe, C | 1 |
| Sakamoto, J | 2 |
| Noguchi, S | 1 |
| Kang, YK | 2 |
| Lee, SS | 1 |
| Yoon, DH | 1 |
| Lee, SY | 1 |
| Chun, YJ | 1 |
| Kim, MS | 1 |
| Ryu, MH | 2 |
| Chang, HM | 2 |
| Lee, JL | 1 |
| Kim, TW | 2 |
| Kamil, M | 1 |
| Haron, M | 1 |
| Yosuff, N | 1 |
| Khalid, I | 1 |
| Azman, N | 1 |
| Jeung, HC | 1 |
| Chung, HC | 1 |
| Wolf, SL | 1 |
| Qin, R | 1 |
| Menon, SP | 1 |
| Rowland, KM | 1 |
| Thomas, S | 1 |
| Delaune, R | 1 |
| Christian, D | 1 |
| Pajon, ER | 1 |
| Satele, DV | 1 |
| Berenberg, JL | 1 |
| Loprinzi, CL | 1 |
| Caronia, D | 1 |
| Sastre, J | 1 |
| de la Torre, J | 1 |
| Alonso, MR | 1 |
| Moreno, LT | 1 |
| Pita, G | 1 |
| Díaz-Rubio, E | 1 |
| Benítez, J | 1 |
| González-Neira, A | 1 |
| Bartal, A | 1 |
| Mátrai, Z | 1 |
| Szûcs, A | 1 |
| Liszkay, G | 1 |
| Gorgulu, S | 1 |
| Celik, S | 1 |
| Tezel, T | 1 |
| Scheithauer, W | 2 |
| Schüll, B | 1 |
| Ulrich-Pur, H | 1 |
| Schmid, K | 1 |
| Raderer, M | 1 |
| Haider, K | 1 |
| Kwasny, W | 1 |
| Depisch, D | 1 |
| Schneeweiss, B | 1 |
| Lang, F | 1 |
| Kornek, GV | 1 |
| Lin, E | 1 |
| Morris, JS | 1 |
| Ayers, GD | 1 |
| Risum, S | 1 |
| Langer, SW | 1 |
| Childress, J | 1 |
| Lokich, J | 1 |
| Park, YH | 1 |
| Ryoo, BY | 1 |
| Kim, SA | 1 |
| Chung, JH | 1 |
| Takahashi, K | 1 |
| Mori, T | 1 |
| Yamaguchi, T | 1 |
| Matsumoto, H | 1 |
| Miyamoto, H | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Katayanagi, S | 1 |
| Narasimhan, P | 1 |
| Narasimhan, S | 1 |
| Hitti, IF | 1 |
| Rachita, M | 1 |
| Kondo, Y | 1 |
| Takemiya, S | 1 |
| Sakamoto, N | 1 |
| Nishisho, I | 1 |
| Lassere, Y | 1 |
| Hoff, P | 1 |
| Heo, YS | 1 |
| Ahn, JH | 1 |
| Lee, JS | 1 |
| Kim, WK | 1 |
| Cho, HK | 1 |
| Ezzeldin, H | 1 |
| Diasio, R | 2 |
| Blum, J | 1 |
| Fischel, JL | 1 |
| Formento, P | 1 |
| Ciccolini, J | 1 |
| Etienne-Grimaldi, MC | 1 |
| Milano, G | 1 |
| Komatsu, Y | 1 |
| Takei, M | 1 |
| Yuki, S | 1 |
| Fuse, N | 1 |
| Furukawa, S | 1 |
| Kato, T | 1 |
| Takeda, H | 1 |
| Kato, M | 1 |
| Asaka, M | 1 |
| Cardinale, D | 1 |
| Colombo, A | 1 |
| Colombo, N | 1 |
| Gugerli, O | 1 |
| Leupin, N | 1 |
| Kurt, M | 1 |
| Aksoy, S | 1 |
| Guler, N | 1 |
| Marini, A | 1 |
| Hengge, UR | 1 |
| Gundling, F | 1 |
| Fuchs, M | 1 |
| Nowak, L | 1 |
| Antoni, D | 1 |
| Hoffmann, E | 1 |
| Schepp, W | 1 |
| Gressett, SM | 1 |
| Stanford, BL | 1 |
| Hardwicke, F | 1 |
| Saif, MW | 1 |
| Elfiky, A | 1 |
| Guedin, P | 1 |
| Chasle, J | 1 |
| Blanc-Fournier, C | 1 |
| Lacroix, J | 1 |
| Wang, Y | 1 |
| Xu, RR | 1 |
| Webster-Gandy, JD | 1 |
| How, C | 1 |
| Harrold, K | 1 |
| Do, JE | 1 |
| Kim, YC | 1 |
| Shimomatsuya, T | 1 |
| Mitsudou, Y | 1 |
| Nakamura, T | 1 |
| Yonezawa, K | 1 |
| Shiraishi, S | 1 |
| Maruhashi, K | 1 |
| Ota, K | 1 |
| Kishida, S | 1 |
| Yucel, I | 1 |
| Guzin, G | 1 |
| Belov, VV | 1 |
| Bordunovskiĭ, VN | 1 |
| Grekova, NM | 1 |
| Lebedeva, IuV | 1 |
| Tertyshnik, SS | 1 |
| Yen-Revollo, JL | 1 |
| Goldberg, RM | 1 |
| McLeod, HL | 1 |
| Trindade, F | 1 |
| Haro, R | 1 |
| Fariña, MC | 1 |
| Requena, L | 1 |
| Lempert, KD | 1 |
| Healy, HG | 1 |
| Clarkson, AR | 1 |
| Jolivet, J | 1 |
| Giroux, L | 1 |
| Laurin, S | 1 |
| Gruber, J | 1 |
| Bettez, P | 1 |
| Band, PR | 1 |
| Maisin, H | 2 |
| Anckaert, MA | 2 |
| De Coster, BM | 2 |
| Lokich, JJ | 1 |
| Moore, C | 1 |
| Hagstrom, WJ | 1 |
| Faibisoff, B | 1 |
| Soltani, K | 1 |
| Robson, MC | 1 |
| McDonald, SG | 1 |
| Peterka, ES | 1 |
| Benoldi, D | 1 |
| Pezzarossa, E | 1 |
| Alinovi, A | 1 |
| Labrini, G | 1 |
| Marcheselli, W | 1 |
| de Panfilis, G | 1 |
| Manfredi, G | 1 |
| Weidmann, B | 1 |
| Teipel, A | 1 |
| Niederle, N | 1 |
| Robben, NC | 1 |
| Pippas, AW | 1 |
| Moore, JO | 1 |
| Burnet, NG | 1 |
| Mason, MD | 1 |
| Hanson, JA | 1 |
| Wurm, R | 1 |
| Peacock, JH | 1 |
| Chiara, S | 1 |
| Nobile, MT | 1 |
| Barzacchi, C | 1 |
| Sanguineti, O | 1 |
| Vincenti, M | 1 |
| Di Somma, C | 1 |
| Meszaros, P | 1 |
| Rosso, R | 1 |
| Iurlo, A | 1 |
| Fornier, M | 1 |
| Caldiera, S | 1 |
| Bertoni, F | 1 |
| Foa, P | 1 |
| Noguerón, E | 1 |
| Berrocal, A | 1 |
| Albert, A | 1 |
| Camps, C | 1 |
| Vicent, JM | 1 |
| Bak, A | 1 |
| Lim, WT | 1 |
| Koo, WH | 1 |
| Au, E | 1 |
| Khoo, KS | 1 |
| Yan, H | 1 |
| Pestieau, SR | 1 |
| Shmookler, BM | 1 |
| Sugarbaker, PH | 2 |
| Barth, G | 1 |
| Basten, O | 1 |
| Rüschoff, J | 1 |
| Rompel, R | 1 |
| Rothenberg, ML | 1 |
| Meropol, NJ | 1 |
| Poplin, EA | 1 |
| Van Cutsem, E | 1 |
| Wadler, S | 1 |
| Doe, EA | 1 |
| Budenz, DL | 1 |
| Gedde, SJ | 1 |
| Imami, NR | 1 |
| Bleiberg, H | 1 |
| Di Leo, A | 1 |
| Abushullaih, S | 1 |
| Saad, ED | 1 |
| Munsell, M | 1 |
| Stone, SP | 1 |
| Labandter, HP | 2 |
| Ryan, RF | 2 |
| Goette, DK | 1 |
| Gartmann, H | 1 |
| Habal, MB | 1 |
| Biano, G | 1 |
| Cavins, JA | 1 |
| Boileau, GA | 1 |
| Klein, E | 1 |
| Murray, JE | 1 |
| Kemeny, N | 1 |
| Seiter, K | 1 |
| Martin, D | 1 |
| Urmacher, C | 1 |
| Niedzwiecki, D | 1 |
| Kurtz, RC | 1 |
| Costa, P | 1 |
| Murray, M | 1 |
| Wright, MM | 1 |
| Grajewski, AL | 1 |
| Cristol, SM | 1 |
| Parrish, RK | 1 |
| Vukelja, SJ | 1 |
| Lombardo, FA | 1 |
| James, WD | 1 |
| Weiss, RB | 1 |
| Altimari, AF | 1 |
| Bhoopalam, N | 1 |
| O'Dorsio, T | 1 |
| Lange, CL | 1 |
| Sandberg, L | 1 |
| Prinz, RA | 1 |
| Watson, KJ | 1 |
| Shulkes, A | 1 |
| Smallwood, RA | 1 |
| Douglas, MC | 1 |
| Hurley, R | 1 |
| Kalnins, R | 1 |
| Moran, L | 1 |
| Sillman, FH | 1 |
| Sedlis, A | 1 |
| Boyce, JG | 1 |
| Bellmunt, J | 1 |
| Navarro, M | 1 |
| Hidalgo, R | 1 |
| Solé, LA | 1 |
| Niehoff, M | 1 |
| Redman, JF | 1 |
| Turley, JT | 1 |
| Weiss, HD | 1 |
| Walker, MD | 1 |
| Wiernik, PH | 1 |
| Moynahan, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1/2, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Subjects With Solid Tumors And ErbB-2 Positive Metastatic Or Locally Advanced Breast Cancer[NCT00741260] | Phase 1/Phase 2 | 105 participants (Actual) | Interventional | 2008-12-09 | Completed | ||
| Double-Blind Phase III Study of Pyridoxine vs Placebo for the Prevention of Capecitabine-induced Hand-Foot Syndrome[NCT00446147] | Phase 3 | 389 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome[NCT00296036] | Phase 3 | 137 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034] | 14 participants (Actual) | Interventional | 2020-08-04 | Terminated (stopped due to Principal Investigator retired before study completed.) | |||
| A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628] | 10 participants (Anticipated) | Interventional | 2012-01-31 | Not yet recruiting | |||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of subjects with Complete Response, Partial Response, or Stable Disease at least 24 weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.
| Intervention | percentage of participants (Number) |
|---|---|
| Prior Lapatinib Subjects | 71.4 |
| Lapatinib Naive Subjects P1 | 72.1 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 73.0 |
Duration of response was measured from the time at which response criteria were met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the first date of recurrence or progressive disease (PD) or death per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00741260)
Timeframe: From start date of response to first PD/death, up to three years.
| Intervention | weeks (Median) |
|---|---|
| Prior Lapatinib Subjects | 48.3 |
| Lapatinib Naive Subjects P1 | 46.3 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 46.3 |
MTD reflects the highest dose of capecitabine in combination with neratinib that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.
| Intervention | mg/m^2 (Number) |
|---|---|
| Capecitabine in Combination With Neratinib | 1500 |
MTD reflects the highest dose of neratinib plus capeciteabine that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.
| Intervention | mg (Number) |
|---|---|
| Neratinib in Combination With Capecitabine | 240 |
Number of participants reporting Adverse Events Causing Dose Limiting Toxicities (DLT). (NCT00741260)
Timeframe: From first dose date to day 21
| Intervention | Participants (Count of Participants) |
|---|---|
| N160 + C1500 | 0 |
| N160 + C2000 | 2 |
| N200 + C2000 | 2 |
| N240 + C1500 | 0 |
| N240 + C2000 | 2 |
| N + C MTD - No Prior Lap | 0 |
| N + C MTD - Prior Lap | 0 |
Number of Subjects with Complete or Partial Response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.
| Intervention | percentage of participants (Number) |
|---|---|
| Prior Lapatinib Subjects | 57.1 |
| Lapatinib Naive Subjects P1 | 63.9 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 63.5 |
A total administered dose of capecitabine until the development of grade 2 or higher hand-foot syndrome during the chemotherapy. (NCT00446147)
Timeframe: Up to 2 years
| Intervention | miligram per square meter (Median) |
|---|---|
| Placebo | 70000 |
| Pyridoxine | 70000 |
Number of patients with any grade of hand-foot syndrome (NCT00446147)
Timeframe: Up to 2 years
| Intervention | participants (Number) |
|---|---|
| Placebo | 55 |
| Pyridoxine | 57 |
A patient self-reported hand-foot syndrome (HFSD), also known as palmar-plantar erythrodysesthesia, was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in either hands or feet were tabulated and percentages are reported. (NCT00296036)
Timeframe: First 3 weeks of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Urea/Lactic Acid Cream | 13.6 |
| Placebo Cream | 10.2 |
Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00296036)
Timeframe: Up to 4, 21-day cycles
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3+ Adverse Event | Grade 4+ Adverse Event | |
| Placebo Cream | 18 | 3 |
| Urea/Lactic Acid Cream | 21 | 3 |
15 reviews available for fluorouracil and Symptom Cluster
| Article | Year |
|---|---|
Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review.
Topics: Adult; Courage; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms; Syndrome | 2022 |
Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review.
Topics: Adult; Courage; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms; Syndrome | 2022 |
Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review.
Topics: Adult; Courage; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms; Syndrome | 2022 |
Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review.
Topics: Adult; Courage; Fluorouracil; Humans; Hyperpigmentation; Male; Stomach Neoplasms; Syndrome | 2022 |
[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
Topics: Antineoplastic Agents; Capecitabine; Cytarabine; Deoxycytidine; Docetaxel; Doxorubicin; Fluorouracil | 2011 |
Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Black People; Capecitabine; Deoxycytidine; Erythema; F | 2004 |
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
Topics: Activities of Daily Living; Algorithms; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitab | 2004 |
Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.
Topics: Antimetabolites, Antineoplastic; Diagnosis, Differential; Dihydropyrimidine Dehydrogenase Deficiency | 2004 |
Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine | 2004 |
Management of hand-foot syndrome induced by capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Foot Injuries; Hand Inju | 2006 |
[Progress of study on prevention and treatment of xeloda induced hand-foot syndrome by measures of Chinese and Western medicine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Therapy; Drugs, Chinese Herbal; F | 2007 |
Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
Topics: Activities of Daily Living; Antineoplastic Agents; Cancer Care Facilities; Cryotherapy; Cytarabine; | 2007 |
[Drug-induced leukoencephalopathy].
Topics: Antineoplastic Agents; Brain Edema; Cisplatin; Cytarabine; Fluorouracil; Humans; Hypertensive Enceph | 2007 |
Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
Topics: Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Enzyme Inhibitors; Fluorouracil; Foot Der | 2008 |
The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy.
Topics: Female; Fluorouracil; Heart Diseases; Humans; Middle Aged; Pyrimidines; Syndrome | 1993 |
Review of erythroplasia of Queyrat and its treatment.
Topics: Adult; Aged; Erythroplasia; Fluorouracil; Humans; Male; Middle Aged; Penile Neoplasms; Precancerous | 1976 |
A review of lower genital intraepithelial neoplasia and the use of topical 5-fluorouracil.
Topics: Acquired Immunodeficiency Syndrome; Administration, Topical; Adult; Anal Canal; Anus Neoplasms; Carc | 1985 |
Neurotoxicity of commonly used antineoplastic agents (first of two parts).
Topics: Animals; Antineoplastic Agents; Asparaginase; Brain; Brain Diseases; Fluorouracil; Humans; Leukemia; | 1974 |
12 trials available for fluorouracil and Symptom Cluster
| Article | Year |
|---|---|
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot | 2014 |
A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cluster Analysis; Cyc | 2017 |
A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluoroura | 2009 |
[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2010 |
Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols | 2003 |
A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progre | 2004 |
[Effects of short-term immunosuppression on the engraftment of skin transplants at syndrome of the diabetic foot].
Topics: Biopsy; Blood Transfusion, Autologous; Diabetic Foot; Female; Fluorouracil; Follow-Up Studies; Graft | 2007 |
Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil | 2002 |
A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Aspartic Acid; Colorectal Neoplasms; | 1991 |
69 other studies available for fluorouracil and Symptom Cluster
| Article | Year |
|---|---|
Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bloo | 2018 |
[A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cilostazol; Combined M | 2019 |
Gut peptide profile and chemotherapy-associated dyspepsia syndrome in patients with breast cancer undergoing FEC60 chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemoth | 2013 |
Gastrointestinal: bevacizumab-induced reversible posterior leukoencephalopathy syndrome in patient with rectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Unilateral Capecitabine-related Hand-foot Syndrome.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon | 2015 |
[Management of hand-foot syndrome in patient treated with capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil | 2008 |
Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice.
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Appetite Stimulants; Body Weight; Cachexia; Cell | 2008 |
[A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy].
Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Fluorouracil; Foot; Hand; Humans; Male; Middle Age | 2008 |
An unusual presentation of hand-foot syndrome at the hidden area: the scrotum and penis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 2009 |
Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasm | 2009 |
Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cell Count; Deoxycytidine; Female; Fluorouracil | 2010 |
High frequency of hand foot syndrome with capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cross-Sectional St | 2010 |
Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erythema; Fl | 2010 |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breas | 2011 |
A case of coronary spasm induced by 5-fluorouracil.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Chest Pain; Colonic Neoplasms; Coronary Angiography; | 2002 |
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms; | 2002 |
[Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response R | 2003 |
Cutaneous hand and foot toxicity associated with cancer chemotherapy.
Topics: Antineoplastic Agents; Docetaxel; Doxorubicin; Drug Eruptions; Erythema; Fluorouracil; Foot; Hand; H | 2003 |
High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluo | 2003 |
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration | 2003 |
Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cli | 2004 |
Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.
Topics: Antineoplastic Agents; beta-Alanine; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Dose-Resp | 2004 |
Treatment of a Gilbert's syndrome patient with irinotecan, leucovorin and 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Gilbert Disease; G | 2005 |
Acute coronary syndrome induced by oral capecitabine.
Topics: Acute Disease; Administration, Oral; Adult; Angina, Unstable; Antimetabolites, Antineoplastic; Bone | 2006 |
[Blisters unlike others].
Topics: Aged; Antimetabolites, Antineoplastic; Blister; Capecitabine; Deoxycytidine; Drug Eruptions; Female; | 2006 |
Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2006 |
[Hand-foot syndrome with capecitabine therapy].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neopl | 2007 |
["Iatrogenic acute coronary syndrome"--59 year old patient with adenocarcinoma of ascending colon and stenocardia while receiving adjuvant chemotherapy with 5-fluorouracil].
Topics: Adenocarcinoma; Angina Pectoris; Chemotherapy, Adjuvant; Colon, Ascending; Colonic Neoplasms; Fluoro | 2006 |
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deficiency Diseases; Deoxycyt | 2006 |
[Breast carcinoma and bone chondrosarcoma: a new syndrome?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Breas | 2006 |
Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; F | 2007 |
[A case of severe hand-foot syndrome caused by capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration | 2007 |
Topical henna for capecitabine induced hand-foot syndrome.
Topics: Administration, Cutaneous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine | 2008 |
Hand-foot syndrome with sclerodactyly-like changes in a patient treated with capecitabine.
Topics: Adenocarcinoma; Administration, Oral; Biopsy, Needle; Capecitabine; Deoxycytidine; Dose-Response Rel | 2008 |
Haemolysis and renal impairment syndrome in patients on 5-fluorouracil and mitomycin-C.
Topics: Aged; Anemia, Hemolytic; Fluorouracil; Humans; Kidney; Kidney Diseases; Male; Mitomycins; Stomach Ne | 1980 |
Renal complications of cytotoxic therapy.
Topics: Animals; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Cytarabine; Dogs; Fluorou | 1983 |
Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome.
Topics: Adenocarcinoma; Adult; Anemia, Hemolytic; Drug Therapy, Combination; Female; Fluorouracil; Humans; K | 1983 |
[Combination chemotherapy and radiotherapy. Differential effect, on the intestinal syndrome, of fractionated irradiation with fractionated drug administration].
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; Female; Fluorouracil; Intestinal Dise | 1982 |
[Combination chemotherapy and radiotherapy. Differential effect, on the medullary syndrome, of fractionated irradiation with fractionated drug administration].
Topics: Animals; Brain Diseases; Disease Models, Animal; Drug Administration Schedule; Female; Fluorouracil; | 1982 |
Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; | 1984 |
Dysplastic nevus syndrome (B-K mole syndrome).
Topics: Dermabrasion; Fluorouracil; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Nevus, Pigmented | 1983 |
Porokeratosis (Mibelli): treatment with topical 5-fluorouracil.
Topics: Administration, Topical; Adult; Fluorouracil; Hand Dermatoses; Humans; Keratosis; Male; Skin; Syndro | 1983 |
[Retinoic acid and 5-FU mixture in the topical treatment of several skin diseases (author's transl)].
Topics: Drug Combinations; Fluorouracil; Humans; Keratosis; Ointments; Radiation Injuries; Skin Diseases; Sy | 1980 |
The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy.
Topics: Adenocarcinoma; Angina Pectoris; Electrocardiography; Female; Fluorouracil; Heart; Heart Diseases; H | 1994 |
Thrombocytopenia with absent radii (TAR) syndrome: a new increased cellular radiosensitivity syndrome.
Topics: Antimetabolites, Antineoplastic; Cell Survival; Chromatids; Fibroblasts; Fluorouracil; G2 Phase; Hum | 1995 |
Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1997 |
Palmar-plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy--an underestimated toxic event?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Erythema; Female; F | 1997 |
[Acute cerebellar syndrome due to 5-fluorouracil].
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cerebellar Ataxia; Fluorouracil; Headache; Humans; M | 1997 |
[A case of Cogan-Reese syndrome (iris nevus syndrome)].
Topics: Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; F | 1997 |
Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Catheterization, Central Venous; Cohort Studies; Colonic | 1999 |
Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 2001 |
Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Digestive Syste | 2001 |
[Clinical and histopathological characteristics of early Leser-Trélat syndrome].
Topics: Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Colon; Colonic Neoplasms; Colonosco | 2001 |
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Fluorouracil; Gastroin | 2001 |
Long-term surgical outcomes of patients with glaucoma secondary to the iridocorneal endothelial syndrome.
Topics: Adult; Antihypertensive Agents; Corneal Diseases; Endothelium, Corneal; Fluorouracil; Follow-Up Stud | 2001 |
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiovascular Diseases; Colorectal Ne | 2002 |
Basal cell nevus syndrome and adenocarcinoma of the colon. Response to systemic fluorouracil.
Topics: Adenocarcinoma; Adult; Carcinoma, Basal Cell; Colonic Neoplasms; Female; Fluorouracil; Humans; Nevus | 1979 |
5-fluorouracil in management of Gorlin's syndrome.
Topics: Aged; Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Skin Neoplasms; Syndrome | 1978 |
5-fluorouracil in Gorlin's syndrome.
Topics: Aged; Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Jaw Diseases; Skin Neoplasms; Syndrome | 1978 |
[Topical use of antineoplastic agents in precancerous conditions of the skin].
Topics: Administration, Topical; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Kera | 1977 |
The "turban" nevoid basal cell syndrome. Current management with surgery, chemotherapy and immunotherapy.
Topics: Adult; Bone Cysts; Carcinoma, Basal Cell; Dinitrochlorobenzene; Fluorouracil; Humans; Jaw Diseases; | 1975 |
5-Fluorouracil after trabeculectomy and the iridocorneal endothelial syndrome.
Topics: Adult; Cataract Extraction; Conjunctiva; Corneal Diseases; Endothelium, Corneal; Fluorouracil; Follo | 1991 |
Pyridoxine for the palmar-plantar erythrodysesthesia syndrome.
Topics: Dermatitis, Exfoliative; Fluorouracil; Hand Dermatoses; Humans; Male; Middle Aged; Nervous System Di | 1989 |
Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 1986 |
Watery diarrhea-hypokalemia-achlorhydria syndrome and carcinoma of the esophagus.
Topics: Achlorhydria; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; | 1985 |
Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil.
Topics: Carcinoma, Squamous Cell; Erythema; Fluorouracil; Foot; Hand; Humans; Male; Middle Aged; Paresthesia | 1988 |
[Case demonstration: Papillomatosis cutis carcinoides (Gottron) in epidermolysis bullosa dystrophica].
Topics: Adult; Bleomycin; Epidermolysis Bullosa; Female; Fluorouracil; Foot; Hand; Humans; Leg; Lymphadeniti | 1974 |
Failure of chemotherapy in treatment of giant condyloma acuminata (Buschke-Loewenstein tumor).
Topics: Adult; Condylomata Acuminata; Fluorouracil; Humans; Male; Penile Diseases; Penis; Plant Extracts; Pl | 1974 |
Multiple basal cell naevus syndrome--successful treatment of basal cell tumours with 5-fluorouracil.
Topics: Adult; Carcinoma, Basal Cell; Dentigerous Cyst; Fluorouracil; Humans; Jaw Diseases; Male; Skin Neopl | 1973 |